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Abstract
Aging and HIV have parallelism in immunode®ciency status because of the appearance of infections
or relapse leading to death in both conditions. HIV-RNA is predictor for HIV progression correlated
with CD4+ depletion. CD4+ and plasma zinc levels (zincaemia) may be predictors for infections relapse
in aging because of zinc relevance for normal immune ecieny against infections and for CD4+ growth.
Moreover, zincaemia decreases in aging and infection. A total of 67 elderly subjects aected by
infections resistant to antibiotic therapy were recruited. A total of 28 HIV+ subjects with HAART
therapy were also used. CD4+ depletion (507 mm3) and zincaemia de®ciency (76 mg/dl), as compared to
CD4+ (700±1100 mm3) and zincaemia (85±100 mg/dl; age 40±75 years) normal ranges, are possible
limits (Cox hazard regression) for severe infections relapse, such as chronic obstructive bronchitis and
bronchopneumonia by bacteria or Candida complication, in aging. CD4+ and zincaemia values are
within the lower limits of normal range in urinary tract infections. Zincaemia and HIV-RNA or CD4+
are inversely correlated (r = 0.57 and r = 0.72, respectively) in HIV+ HAART treated subjects.
Consequently there is no appearance of opportunistic infections. Parallelism between aging and HIV
may exist because of the resemblance in marked zinc de®ciency and CD4+ depletion with high scores in
relative risks for severe infections relapse. Supplementing zinc (12 mg Zn++/day) for one month in
infected elderly subjects and HAART therapy in HIV+ subjects reduces risk scores in CD4+ and
zincaemia de®ciencies for infections relapse, suggesting that the zinc bene®cial eect may be independent
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either by HIV-virus or pathogen agents involved. While HAART may reduce the occurrence of
opportunistic infections in HIV by means of also major zinc bioavailability, supplementing zinc can be
recommended in elderly people as resistence to infections. Since zinc de®ciecy is correlated with CD4+
depletion, this latter may also be good diagnostic marker to detect `clear immunode®cency' in aging, as
in HIV condition. # 1999 International Society for Immunopharmacology. Published by Elsevier
Science Ltd. All rights reserved.
Keywords: Aging; HIV; Zinc; CD4+; HIV-RNA; Infection relapse; Risk factors
1. Introduction
Aging and HIV have parallelism in immunode®ciency status because of the appearance of
infections or relapse leading to death in both conditions (Pawelec & Solana, 1997). Proteases
inhibitors reduce opportunistc infections (Chaisson & Moore, 1997) because of HIV-RNA
relevance for HIV progression as major predictor (Mellors, Rinaldo, Gupta, White, Todd &
Kingsley, 1996), other than CD4+ depletion (Levy, 1989). CD4+ count dysregulation causes
infections or infections recidive (Pawelec & Solana, 1997). No speci®c immunological limits
under which risk of infection or infection relapse are still available in aging. Together with
CD4+, zinc may be a predictor because: (i) zinc is important for immune eciency against
infections (Sugarman, 1983); (ii) zinc is predictor for death in comatose patients for high
frequency of infectious episodes (Mocchegiani, Imberti, Testasecca, Zandri, Santarelli & Fabris,
1995a); (iii) zinc de®ciency is a cofactor for infections in old age (Chandra, 1989). Finally zinc
aects CD4+ maturation and dierentiation (Beck, Prasad, Kaplan, Fitzgerald, & Brewer,
1997). Moreover zinc decreases in aging (Fabris, Mocchegiani, Amadio, Zannotti, Licrasto &
Franceschi, 1984) and during infections (Mocchegiani Veccia, Ancarani, Scalise, & Fabris,
1995b; Sandstead, 1994; Shankar & Prasad, 1998), whereas CD4+ depletion occurs during
infections (Pawelec & Solana, 1997). In turn, infections and infections relapse are constant
events in aging (Fabris & Mocchegiani, 1995). Plasma zinc levels (zincaemia) and CD4+ are
tested in infected elderly subjects from remission phase as possible limits and, as such, possible
risk factors for infections relapse resistant to conventional antibiotic therapy (Lewis & Reeves,
1994). Peripheral T-cells are used to give more complete picture of generalized
immunode®ciency in aging, as in canine bronchoalveolar infections (Dirscherl, Beisker,
Kremmer, Mihalkov, Voss & Ziesenis, 1995). HIV model with HAART therapy was used to
further study the possible parallelism between HIV and aging for infections relapse incidence.
Because of zincaemia heterogeneity in aging (Fabris et al., 1984; Prasad, Fitzgerald, Hess,
Kaplan, Pelen & Dardenne, 1993) and HIV (Fabris, Mocchegiani, Galli, Irato, Lazzarin &
Moroni, 1988; Mocchegiani et al., 1995b), total thymulin (TT) (active zinc-bound ZnFTS +
inactive zinc-unbound FTS) and active thymulin (ZnFTS) (AT) ratio, which is the unsaturated
fraction of thymulin (FTS) by zinc ions (Fabris et al., 1984) is a good marker to detect real
zinc de®ciency because of the inverse strict correlation between zincaemia status and the ratio
itself (Fabris et al., 1984). Thus, zincaemia was associated with TT/AT ratio. Supplementing
zinc from remission phase was carried out in elderly subjects aected by pre-existing chronic
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obstructive bronchitis. Relative risk factors were calculated from the remission phase (time 0)
of infection to month 4 of observation. An HIV model was used as comparison.
2. Subjects and methods
2.1. Elderly subjects
A total of 48 male and 19 female subjects (63±75 years, mean 692 5.8) admitted to the
hospital were recruited in remission phase (time 0) of infection (urinary tract, chronic
obstructive bronchitis and bronchopneumonia by bacteria or candida complication). Old
patients are divided according to infections. Group A with urinary tract infections (18 subjects,
5 male and 13 female, mean age 7025 years), group B with chronic obstructive bronchitis (36
subjects, 25 male and 11 female, mean age 6724 years) and group C with bronchopneumonia
by bacteria or candida complication (13 subjects, 10 male and 3 female, mean age 6823.5
years). Elderly patients with previous infections associated with other pathological conditions
were excluded. Conventional antibiotic therapy was used before remission phase. Length of
conventional antibiotic treatment was of 1222.0 and 1422.7 days before time 0 (Data are the
mean number of days of antibiotic treatment) for group A and for groups B and C,
respectively, with conventional therapeutic dose dependent by infection severity. No other
drugs were administered other than Vitamins B complex in order to maintain a good balance
of vitamins B by intestinal bacterial ¯ora, which can be destroyed by antibiotic therapy. Blood
withdrawal (time 0) was perfomed in remission phase of infection. The daily diet was similar to
healthy old controls. Double-blinded controlled trial with zinc at the dose of 12 mg Zn++/day
(USDA, 1976) or placebo (starch containing capsule) was carried out for one month in 15 (13
male and 2 female, mean age 6823 years) and 14 (11 male and 3 female, mean age 6622
years) elderly people subjects, respectively, after one week from remission phase of infection
(chronic obstructive bronchitis). Relative risk factors as well as possible infection relapse were
evaluated from month 0 to 4 of observation. Supplementing zinc was carried out in chronic
obstructive bronchitis because of more common infection relapse in aging (Pawelec & Solana,
1997) with consequent major subjects availability.
2.2. HIV+ subjects
A total of 21 male and 7 female intravenous drug-users HIV+ subjects (20±36 years, mean
2825.5) were recruited with CD4+ number between 250 and 400 mm3 (Stage III of disease)
(Murray et al., 1985). Because of HIV-RNA as predictor for HIV progression (Mellors et al.,
1996) with HAART to block virus replication (Sepkowitz, 1998), the medical ethic suggested to
immediatly perform HAART when CD4+E400±500 mm3 and HIV-RNAe10,000 copies/ml
(Sepkowitz, 1998). No other drugs administered other than HAART [2 nucleoside analogues
(AZT + 3TC) and 1 proteases inhibitor (IND or RIT)] at standard doses/day (Sepkowitz,
1998), with compliance of 92%. HIV-RNA, immunological and nutritional parameters were
detected at months 0 and 4 after HAART therapy as well as possible opportunistic infections
censoring. Relative risk factors were evaluated from month 0 to 4 of observation. The data of
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relative risk factors were compared with HIV+ subjects (18 subjects) with CD4+ between 250
and 400 mm3 treated with only AZT because of no availability of other antiviral drugs in this
retrospective study (Mocchegiani et al., 1995b). The daily diet was similar to young healthy
controls. No vegetarian subjects were present. ELISA and Western blot con®rmed HIV
seropositivity.
2.3. Control groups
Seven men and eight women healthy young subjects (2523.4 years) admitted to the hospital
for minor surgery served as controls. Five men and ten women healthy elderly subjects (672
4.6 years) were recruited in accordance to immunogerontological `SENIEUR protocol'
(Ligthart et al., 1984). Vegetarian subjects were excluded. They were recruited and examined
according to the guidelines of Helsinki declaration. The informed consensus for blood
withdrawls as well as for zinc trial was obtained.
2.4. Methods
HIV-RNA plasma detection was performed by means of RT-PCR ampli®cation of speci®c
primers (SK38, SK39) (Menzo, Bagnarelli, Giacca, Manzin, Varaldo & Clementi, 1992). TT/
AT ratio were tested in the plasma by inhibiting azathioprine-sensitive rosettes assay (Fabris et
al., 1984). Zincaemia was tested using A.A.S. (Fabris et al., 1984). CD4+ absolute number was
counted with cyto¯uorimetry (Epics V, Culter, USA) using Leu3a FITC (Becton-Dickinson,
USA). Dierences were compared using ANOVA (two-way). Cox hazard regression (Matthews
& Farewell, 1988) was used to test relative predictors (CD4+ and zincaemia) for infection risks
and for possible limits under which rinfections risk may be high. Least-square method and
analysis of covariance were used for correlations and to test signi®cance among regression
lines, respectively. Dierences were signi®cant when PE0.05.
Table 1
Immunological and nutritional parameters in elderly subjects in remission phase of infection (time 0)a
Groupsb Ratio T.T./A.T. (logÿ2) Zincaemia (mg/dl) CD 4
+ (mm3) No of infections/subjects
A 2.020.3 83.324.0 696258 18/18
B 2.520.3 75.323.2 457253 13/13
C 2.420.2 76.824.3 460266 36/36
D 1.620.2 88.525.8 877247
E 1.120.2 120.026.5 925268
a P<0.01 and P<0.05 when compared to group D.
b A=Elderly subjects (n=18) with pre-existing infections (urinary tract); B=Elderly subjects (n=13) with pre-
existing infections (bronchopneumonia by bacteria or Candida complication); C = Elderly subjects (n = 36) with
pre-existing infections (Chronic obstructive bronchitis); D=Elderly age-matched healthy controls (n=15) (age 60±
73 years); E=Young healthy controls (n=15) (age 20±30 years).
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3. Results
3.1. Elderly subjects
TT/AT ratio >2 (Groups B and C) is associated with more marked zinc de®ciency as
compared to TT/AT ratio (=1.6) and zincaemia values of old healthy controls (P < 0.01)
(Table 1). The anamnestic analysis at time 0 (remission phase) shows that urinary infections
(18/18 patients), bronchopneumonia [by bacteria (8/13 patients) or by Candida complication
(5/13 patients)] and chronic obstructive bronchitis (36/36 patients) are pre-existing infections.
CD4+ count is reduced (groups B and C) (P < 0.01), whereas no dierence in group A as
compared to old healthy controls (Table 1). CD4+ (437249 mm3) and zincaemia (7423.4 mg/
dl) values in old patients aected by bronchopneumonia by Candida complication are not
dierent as compared to those ones by bronchopneumonia by bacteria complication (CD4+=
478 2 62 mm3; zincaemia = 76 2 3.8 mg/dl). No dierences in CD4+ and zincaemia exist
between old patients aected by chronic obstructive bronchitis and by bronchopneumonia
(Table 1), as well as between male and female (data not shown). CD4+ and zincaemia values
for urinary tract infections are included within the normal range (Table 1). Supplementing zinc
for one month from remission phase (time 0) in elderly subjects aected by chronic obstructive
bronchitis increases CD4+ cell number (from 462248 time 0 to 690241 time 1 month; P<
0.01) with signi®cant reduction of infections relapses (2 relapses/15 patients = 13.3%) as
compared to placebo group (6 relapses/14 patients = 42.8%) (P < 0.01) at month 4 of
observation. CD4+ depletion and zinc de®ciency in placebo group are relative risk factors for
infections relapse with signi®cant scores as compared to old zinc-treated group (Table 2).
Moreover, taking into account CD4+ and zincaemia normal ranges (700±1100 mm3; 20±75
years; 85±100 mg/dl; 40±75 years, respectively) from our laboratory, CD4+ (507 mm3) (range
454±530) and zincaemia (76 mg/dl) (range 75±91) may be possible limits at borderline for
chronic obstrucutive bronchitis infections relapse. When the data of zincaemia from old
infected patients before and after zinc supplementation and respective healthy controls are
plotted against the corresponding values of CD4+, signi®cant positive inverse correlation is
found (r=0.81 P<0.01).
Table 2
Relative risk factors for chronic obstructive bronchitis relapse in elderly subjects treated with zinc and for opportu-
nistic infections in HIV+ subjects treated with AZT (retrospective study) or HAART
Covariates Coe. Regr. Rel. Risk z-statistic Coe. Regr. Rel. Risk. z-statistic
Placebo (n=14) Zinc treatment (n=15)
CD4+ 0.82 2.27 P<0.01 0.36 1.44 P>0.05
zincaemia 0.71 2.03 P<0.01 0.41 1.51 P>0.05
HIV+ (AZT treatment) (n=18) HIV+ (HAART treatment) (n=28)
CD4+ 0.78 2.18 P<0.01 0.51 1.67 P>0.05
zincaemia 0.85 2.34 P<0.01 0.48 1.62 P>0.05
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3.2. HIV+ subjects
TT/AT ratio>2 is associated with more marked zinc de®ciency at time 0 as compared to
day 120 of observation (Table 3). CD4+ and body weight (D%) are reduced at time 0 as
compared to young healthy controls (P < 0.001) (Tables 3 and 1). HAART increases
zincaemia, body weight and CD4+ and reduces HIV-RNA (copies/ml) as compared to time 0
(P < 0.01) (Table 3). This reduction is also >1 log10. HAART avoids CD4
+ depletion and
zinc de®ciency as relative risk factors for opportunistic infections, as compared to AZT HIV+
treated subjects (Table 3). HAART induces no appearance of opportunistic infections during
the period of observation as compared to AZT treated group (Stage III of disease) of the
restrospective study (0 infections vs 13 opportunistic infections among whom, three by
Candida) (Mocchegiani et al., 1995b). No dierence between male and female and between
drug-users and heterosexsuals is found (data not shown). Signi®cant inverse correlations exist
between zincaemia and HIV-RNA (r = 0.57; P< 0.05), between CD4+ and HIV-RNA (r =
0.72, P < 0.01) and between zincaemia and body weight (r = 0.76, P < 0.01) in HAART
treated HIV+ subjects.
4. Discussion
CD4+ depletion and marked zinc de®ciency are cross-linked in elderly subjects for infections
relapse, such as bronchopneumonia and chronic obstructive bronchitis, resistant to
conventional antibiotic therapy. HAART induces no appearance of opportunustic infections
because of increased CD4+ and zincaemia values, which are both inversely correlated with
HIV-RNA. HAART reduces also CD4+ and zincaemia relative risk factors for opportunistic
infection incidence. Supplementing zinc in elderly infected subjects restores CD4+ cell number
with signi®cant infections relapse reduction, as it occurs in HIV+ HAART treated subjects.
Thus marked zinc de®ciency and CD4+ depletion may be considered as probable predictors
for infections relapse in aging with HIV parallelism.
CD4+ number is similar in young and old subjects (Cakman Rohwer, Schutz, Kirchner, &
Rink, 1996). FasL-apoptosis by bacteria endotoxins may cause CD4+ dysregulation with
consequent increased bacteria infections relapse (Pawlec & Solana, 1997; Castro, Bremer,
Table 3
CD4+, zincaemia and HIV-RNA in HIV+ subjects treated with HAART from day 0±120 of observationa
Ratio TT/AT (logÿ2) Zincaemia (mg/dl) CD4
+ (mm3) HIV-RNA (copies/ml) Body weightb (D%)
t0 2.3320.2 78.426.4 350238 28.1529.36 ÿ1.7721.23
t120 0.9720.2
 95.625.5 575241 2.4921.91 +0.5120.27
a P<0.01 and P<0.05 when compared to time 0. No opportunistic infections occur in HIV+ HAART treated
subjects during the period of observation.
b The body weight was calculated as individual variance (D%) of the body weight from day 0±120 for each patient.
The signi®cance of D%=w2 test.
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Nobrega, Countinho, & Trua-Bachi, 1998). Indeed, CD4+ depletion is signi®cant in presence
of pre-existing infections (bronchopneumonia and chronic obstructive bronchitis). Such a
depletion may be more related to previous infections rather than to conventional antibiotic
therapy eect because of the blood withdrawals in remision phase and because of the non-
in¯uence of antibiotics (independently by doses used or pathogen agent involved) on altered
CD4+ subsets in peripheral blood by adult infected subjects (Kawakami et al., 1997),
con®rming also, at least, the antibiotic therapy poor ecacy in elderly infected subjects (Lewis
& Reeves, 1994). Zincaemia and CD4+ decrease during infections (Pawelec & Solana, 1997;
Fabris et al., 1988; Mocchegiani et al., 1995b; Sandstead, 1994), which often are, in turn, age-
associated diseases (Fabris & Mocchegiani, 1995). Because of no availability of speci®c
immunological limits under which infection relapse risk may be high in old age, zincaemia and
CD4+ may be taken into account because: (i) zinc is important for immune eciency against
infections by virus, fungi and bacteria (Sugarman, 1983); (ii) zinc de®ciency is a predictor of
death in comatose patients suering by numerous infectious episodes (Mocchegiani et al.,
1995a); (iii) zinc de®ciency is a cofactor for infection in aging (Chandra, 1989); (iv) zinc shows
an age-related decrease (Fabris et al., 1984) and it is essential for CD4+ maturation and
growth (Beck, Prasad, Kaplan, Fitzgerald & Brewer, 1997). Following that, zinc de®ciency and
CD4+ decrement may be cross-linked with possible limits under which infections relapse risk
may be high. Because of no immune dierences between chronic obstructive bronchitis and
bronchopneumonia, such limits may be the same and both are reduced as compared to CD4+
(Hannet, Erkeller-Yuksel, Lydyard, Deneys, & DeBruyere, 1992) and zincaemia normal ranges
(Fabris et al., 1984). CD4+ and zincaemia limits are within the lower limits of normal ranges
in urinary tract infections. Thereby, these latter may be considered as `moderate', whereas the
others as `severe' (Laurence, 1993). Without excluding other T-subsets dysregulations, such as
`memory' and `naive' T-cells, in aging (Sansoni et al., 1993) and in infections (Pawelec &
Solana, 1997), because of signi®cant inverse correlation between CD4+ and zincaemia in
remissed elderly infected subjects, the determination of CD4+ may also be good diagnostic
marker to detect `clear immunode®ciency' in aging, because of good CD4+ number
maintenance (700 mm3) for good health (successful of aging) in centenarians (Sansoni et al.,
1993).
The parallelism between aging and HIV may exist because, other than similar T-cell
dysregulations (Ullum, Lepri, Victor, Skinhoj, Phillips & Pedersen, 1997), strong CD4+
depletion associated with marked zinc-de®ciency causes the appearance of `severe'
opportunistic infections, including Candida aesophagea, in HIV+ subjects (Murray et al., 1985;
Mocchegiani et al., 1995b). The pathogen agent involved is quite dierent between HIV and
aging. Because of the lack of dierence in CD4+ depletion between bronchopneumonia by
Candida and bacteria complication while, one hand possible dierent immune responses by
dierent pathogen agents may be avoided (Belkaid et al., 1994); on the other hand, the
parallelism with HIV in CD4+ depletion for `severe' infections may be further supported.
Indeed supplementing zinc reduces infections relapse with low scores in CD4+ and zincaemia
relative risk factors in elderly infected subjects, as it occurs in HIV+ zinc-treated subiects
(Mocchegiani et al., 1995b). This suggests that zinc may induce resistence against infections
(Shankar & Prasad, 1998). On the other hand resistence to respiratory and urinary infections
in instituzionalized elderly subjects (Girodon et al., 1997) and in Down's syndrome (Licastro et
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al., 1994) is observed during supplementing zinc. In addition, bene®t of physiological zinc
against gram-negative infections has been reported (Wellinghausen et al., 1996). A further
evidence of zinc de®ciency relevance for infections incidence comes from the AZT poor
ecacy, as compared to HAART (Hazura & Kuo, 1997), in HIV condition. Indeed, HAART
increases CD4+ cells number and zincaemia values, which are both inversely correlated with
HIV-RNA, and, consequently, there is no appearance of opportunistic infections. The
disappearance of CD4+ depletion and zinc de®ciency as possible relative risk factors for
opportunistic infections exclusively during HAART therapy (Table 2), is in line with this
interpretation. The HAART eect may also occur by means of major zinc bioavailability due
or to decreased acute in¯ammation (Chandra, 1992) or to better zinc intestinal absorption, as
shown by body weight increments. Because of the absence of zinc in HAART drugs (Veccia,
unpublished observation), these ®ndings together with the eect of zinc supplementation in
elderly subjects (in the present study) and in HIV+ subjects (Mocchegiani et al., 1995b), while
one hand suggest the real ecacy of HAART, on the other hand pin-point zinc as bene®cial
against `severe' infections, whose eect may be independent either by HIV-virus or by other
pathogen agents involved. Moreover, such an eect may be more addressed to the extracellular
matrix because of the disappearance of Candida aesophagea relapse in HIV+ zinc-treated
subjects (Mocchegiani et al., 1995b). While HAART reduces infections occurrence in HIV by
means of also major zinc bioavailability, this latter may be acquired by zinc supplementation
in aging. Other micronutrients or vitamins de®cits have been suggested as infection predictors
(Chandra, 1989). Without excluding that, Vitamin A supplementation has been found
deleterious on immune response in elderly people, whereas zinc prevents infections (Fortes et
al., 1998)Ðfurther supporting, this latter, the relevance of zinc de®ciency in infected elderly
patients during the remission phase. Intestinal malabsorption (Lee, Prasad, Hydrick-Adair,
Brewer, & Johnson, 1993) or in¯ammation (Chandra, 1992) may cause zinc loss in aging.
Whatever causes, low zinc bioavailability is associated with CD4+ depletion, despite zinc
content into young and old human lymphocytes has been found similar (Bunker, Hinks,
Lawson, & Clayton, 1984), whereas it is dierent for others (Prasad et al., 1993). The free
quota of zinc available is more relevant because zinc into lymphocytes (Yurkow & Makhijani,
1998) is more bound with zinc-binding metallothioneins, which are increased in aging
(Mocchegiani, Muzzioli, Cipriano & Giacconi, 1998) and in infections (Sobocinski, Canterbury,
Mapes, & Dinterman, 1995). Since Atomic Absorption Spectrophotometry (AAS) detects zinc-
bound and zinc-unbound, the measure of zinc into lymphocytes may, therefore, result
controversial and, at least, also misleading. Other zinc de®ciency markers, such as ecto-5
nucleotidase, are useful (Prasad et al., 1993). However, TT/AT ratio purchases peculiar role to
test real zinc de®ciency because TT/AT ratio detects zinc ions bioavailability due to strict
inverse correlation between zincaemia status and ratio itself. Moreover TT/AT ratio>2 (logÿ2)
is always associated with more marked zinc de®ciency, as compared to TT/AT ratio = 1
(logÿ2) in presence of normal plasma zinc values (Fabris et al., 1984). Thus the low zinc ions
bioavailability is evident in aging leading to CD4+ depletion and to the appearance of
infections relapses. Thereby, the cross-linking between zinc de®ciency and CD4+ depletion in
aging may be probable relative risk factor avoided by supplementing zinc.
In conclusion, present data, despite obtained in limited number of subjects, may suggest
parallelism between aging and HIV because of the resemblance in CD4+ depletion and zinc
E. Mocchegiani, et al. / International Journal of Immunopharmacology 21 (1999) 271±281278
de®ciecy as relative risk factors for `severe' infections relapse. Because of CD4+ apoptosis
involvement in both conditions (Castro et al., 1998; Algeciras, Dockrell, Lynch, & Paya, 1998),
and, in turn, apoptosis may be directly (Sunderman, 1995) or indirectly (Shankar & Prasad,
1998) prevented by zinc, the resemblance may be further supported. New concepts on cause/s
of `immunosenescence' (Pawlec & Solana, 1997) may be thereby added with an emphasis on
zinc.
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